JAZZ Jazz Pharmaceuticals plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JAZZ

Price (delayed)

$114.26

Market cap

$7.19B

P/E Ratio

95.22

Dividend/share

N/A

EPS

$1.2

Enterprise value

$11.63B

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
Jazz Pharmaceuticals's net income has surged by 192% QoQ
The company's EPS has surged by 183% QoQ
Jazz Pharmaceuticals's quick ratio has decreased by 33% from the previous quarter and by 24% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: TEVA

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
62.96M
Market cap
$7.19B
Enterprise value
$11.63B
Valuations
Price to earnings (P/E)
95.22
Price to book (P/B)
2.07
Price to sales (P/S)
1.9
EV/EBIT
62.44
EV/EBITDA
14.35
EV/Sales
3.07
Earnings
Revenue
$3.79B
EBIT
$186.33M
EBITDA
$810.55M
Free cash flow
$1.24B
Per share
EPS
$1.2
Free cash flow per share
$19.7
Book value per share
$55.27
Revenue per share
$60.12
TBVPS
$64.66
Balance sheet
Total assets
$11.2B
Total liabilities
$7.71B
Debt
$5.78B
Equity
$3.49B
Working capital
$1.67B
Liquidity
Debt to equity
1.66
Current ratio
2.06
Quick ratio
1.41
Net debt/EBITDA
5.48
Margins
EBITDA margin
21.4%
Gross margin
86.9%
Net margin
2.1%
Operating margin
5.1%
Efficiency
Return on assets
0.7%
Return on equity
2.4%
Return on invested capital
2.6%
Return on capital employed
1.9%
Return on sales
4.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-0.2%
1 week
-6.13%
1 month
-9.37%
1 year
-26.59%
YTD
-28.28%
QTD
-11.73%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$3.79B
Gross profit
$3.3B
Operating income
$192.7M
Net income
$79.95M
Gross margin
86.9%
Net margin
2.1%
Jazz Pharmaceuticals's net income has surged by 192% QoQ
The company's net margin has surged by 191% QoQ
JAZZ's operating margin is down by 26% year-on-year
The operating income has declined by 22% year-on-year

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
JAZZ P/E details
P/E
95.22
P/B
2.07
P/S
1.9
EV/EBIT
62.44
EV/EBITDA
14.35
EV/Sales
3.07
The company's EPS has surged by 183% QoQ
Jazz Pharmaceuticals's equity has increased by 27% YoY
The price to book (P/B) is 23% lower than the last 4 quarters average of 2.7 and 17% lower than the 5-year quarterly average of 2.5
The price to sales (P/S) is 39% less than the 5-year quarterly average of 3.1 and 21% less than the last 4 quarters average of 2.4
The revenue has grown by 6% YoY

Efficiency

How efficient is Jazz Pharmaceuticals business performance
The return on equity has surged by 189% since the previous quarter
The company's return on assets has surged by 188% QoQ
The company's return on sales fell by 17% YoY
JAZZ's ROIC is down by 3.7% YoY

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 45% greater than the total liabilities
The company's current ratio fell by 35% QoQ and by 35% YoY
Jazz Pharmaceuticals's quick ratio has decreased by 33% from the previous quarter and by 24% YoY
The company's debt is 66% higher than its equity
Jazz Pharmaceuticals's equity has increased by 27% YoY
Jazz Pharmaceuticals's debt to equity has decreased by 21% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.